FDA grants breakthrough therapy designations for canakinumab to treat periodic …

FDA grants breakthrough therapy designations for canakinumab to treat periodic …

… since 2009 to treat cryopyrin-associated periodic syndrome, Muckle-Wells syndrome and familial cold autoinflammatory syndrome in patients 4 years and older. In 2013, it was approved to treat systemic juvenile idiopathic arthritis in patients 2

(Visited 1 times, 1 visits today)
5
Like
Save

Comments

Write a comment

*